Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized study of Tiscover versus AS210 for chronic arterio-venous leg and foot ulcers
NL-OMON23091Phase 2Active, not recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Aug 2012
- Modality
- Cell Therapies, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 2 trial of Tiscover, AS210 in stasis ulcer, Mixed venous-arterial leg ulcer (MVALU), foot ulcer, sponsored by Vrije University Medical Center. Started Aug 2012; status: active, not recruiting.
02
Drugs
TiscoverAS210
03
Conditions
stasis ulcerMixed venous-arterial leg ulcer (MVALU)foot ulcer
Beyond the preview
Go deeper on NL-OMON23091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON23091.